NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional): PA-27-102

NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional): PA-27-102

The NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional), announcement number PA-27-102, is a high-leverage federal parent NOFO for U.S. small businesses that need an innovation-to-commercialization pathway with a nonprofit research partner. This is not a one-off thematic grant; it is a broad parent-family mechanism used by NIH institutes and centers as a standard entry point for STTR applications.

What makes PA-27-102 especially relevant in a 2026/2027 planning cycle is the explicit multi-wave submission model, open dates, and NIH-level process stability. The opportunity remains a good option for entrepreneurs and small teams working in health, engineering, diagnostics, biomedical software, therapeutics-related tools, and other missions where commercialization potential can be shown. It is officially posted with multiple standard NIH due dates and open windows, and it explicitly states that both non-clinical and clinical-trial-related proposals can be submitted.

This page is a practical guide. It is not legal advice and does not replace the official NOFO language.

Quick reference: at-a-glance details

What PA-27-102 is designed to do

STTR is the NIH mechanism for technology transfer in which the commercializing entity is a small business and the scientific execution includes a formal R&D collaboration with a nonprofit research institution. The STTR intent is straightforward: reduce the disconnect between lab-based discovery and market-ready medical, biotech, digital health, diagnostic, or life-science solutions.

The NOFO states that STTR projects support feasibility and later-stage R&D to develop a commercial product, while reminding applicants that the award is made to the small business concern. The STTR PI may be employed at the SBC or the partnering nonprofit, but the applicant entity is still the small business.

The funding model is not a simple innovation prize. It is an application-and-review process with defined phases and milestone logic:

• Phase I: feasibility of the R&D approach.
• Phase II: expansion and commercialization progress.
• Fast-Track: submit Phase I and Phase II together.
• Direct-to-Phase II: allowed for NIH under specific conditions where scientific/technical readiness is already established and a direct Phase II submission is stronger than a fresh Phase I.

The announcement also points applicants to related opportunities where project fit is better served by SBIR or commercialization-readiness pathways (for example PA-27-100, PA-27-101, and PAR-27-098). That distinction matters: if your project does not depend on a nonprofit partner, STTR is often the wrong track.

Why this opportunity is strategically valuable for 2026/2027 applicants

Federal innovation funding usually comes in two forms: narrow programs tied to one scientific domain and broad parent programs tied to common mechanisms. PA-27-102 sits in the second category. You can apply without a narrow mission filter at application time, but your project still has to be accepted by an NIH Institute or Center based on mission relevance and standard merit review quality.

For 2026 and 2027 this matters because:

1. Multiple application windows are available for the same NOFO lifecycle.
2. Phase-based flexibility allows teams at different maturity levels to enter through a route that matches evidence readiness.
3. Clinical trial optional status gives room for both tool-development projects and translational projects that already require human studies.
4. Non-responsive checks and overlap restrictions are known and manageable if you plan early. Many teams lose time because they discover restrictions only after submission.

If your goal is to build health impact plus commercialization viability, PA-27-102 gives a structured route with clear progression logic and defined review norms.

Eligibility and fit (read this carefully)

Who can apply

The opportunity is only for United States small business concerns (SBCs). That includes entities that must satisfy the core ownership and size rules at award time and can be subject to broader SBA governance criteria in 13 C.F.R. Part 121. Among the practical high-level requirements:

• For-profit structure with U.S. business footprint.
• Not more than 500 employees (including affiliates), when applied under the NOFO’s organizational rules.
• Ownership/control limits including U.S. ownership expectations and venture-backed limitations for specific ownership structures.
• Business concerns with more than 50% ownership by multiple VC operating companies, hedge funds, private equity firms, or combinations are explicitly excluded.

If your cap table is unusual (multiple holding layers, investment entities, mixed non-U.S. ownership), this is where teams often stall. These rules are technical and should be reviewed before you start a full draft.

What this means in practice for teams

• Early-stage deep-tech startup: usually strong fit for Phase I if the technical concept is still proof-of-concept heavy.
• Research-heavy company with a clear partner institution: strong fit for STTR if formal collaborative effort can be documented.
• Company proposing a solo execution model: may be better on an SBIR parent (not STTR).
• Any applicant planning both NIH and non-NIH grant routes simultaneously: check duplicate/submission restrictions; this NOFO explicitly disallows some identical/overlapping parallel submissions.

PI and team registration requirements

The NOFO requires proper PD/PI compliance:

• All PD/PI accounts must be set up in eRA Commons.
• ORCID must be present and linked.
• If the same person has dual roles (e.g., signing official), systems may require separate accounts.
• Organizations need active SAM registration and related identifiers (including UEI), plus other upstream system prerequisites for NIH submission.

This is non-negotiable. A proposal can be technically excellent but fail if registration/identity requirements are incomplete.

Application format: tracks, components, and budget mechanics

PA-27-102 supports these application forms:

• New (Phase I, Fast-Track, Direct Phase II)
• Renewal (Phase II)
• Resubmission and Revision where allowed

Clinical trials are optional. However, if you propose a trial:

• You still need all usual NIH and system compliance items.
• A required Regulatory Plan attachment is triggered.
• Clinical trial design feasibility and execution governance are reviewed more heavily.

Budget expectations

Award budget and support are tied to direct/indirect/fee combined total and often constrained by SBA budget guidelines, with NIH component-specific variations. In the official budget table, many NIH components report explicit caps (for example $400,000 or $700,000 Phase I and up to around $2.5M–$3.0M Phase II), while several components show “SBA Guideline” rather than fixed numeric caps.

Practical implication:

• Do not overfit to a single budget number until you confirm the intended NIH component and topic area.
• Contact the relevant participating NIH component early if you need higher than table guidance.
• Build your budget around what the work plan can reasonably achieve in the assigned phase.

Project duration

NIH statutory norms remain in play:

• Phase I: normally up to 1 year.
• Phase II: normally up to 2 years.

Use period length as an evidence tool: scope and schedule should reflect feasible milestones, not generic ambition.

Key timeline and what those dates imply for planning

The NOFO provides explicit due cycles:

• September 5, 2026
• January 5, 2027
• April 5, 2027

All deadlines are due at 5:00 PM local time of the applicant organization.

No late applications are accepted.

There is also an earliest submission date, and an expiration date tied to the funding opportunity window. In planning terms, applicants should not treat the date as a soft preference. NIH-style deadlines in this space are treated as hard deadlines.

Recommended internal planning rhythm

• T-minus 8 to 12 weeks: partner alignment and fit confirmation.
• T-minus 6 weeks: finalize PI and ORCID/eRA/Common/SAM check.
• T-minus 4 weeks: pre-draft all forms and attachments.
• T-minus 2 weeks: internal review of compliance items and budget rationale.
• T-minus 5–7 days: run a “submission stress test” in your system path (ASSIST or Grants.gov route).
• Submission day: leave room for error correction.

If you miss one round, do not treat that as terminal. Use subsequent cycle windows to strengthen and resubmit.

What reviewers are scoring and how to prepare your package

The announcement links review to standard NIH criteria plus STTR-relevant expectations. You should assume review will examine:

1. Significance (why the problem matters)
2. Approach (how technically executable the plan is)
3. Innovation (what is new, not just incremental)
4. Investigator/team capability (execution competence and fit)
5. Commercialization viability for Phase II/Fast-Track where applicable
6. Budget and project duration alignment

For clinical-trial applications, additional scrutiny applies around trial leadership, timeline realism, data flow, regulatory readiness, and multicenter operational design.

For STTR specifically, teams are usually stronger when they demonstrate:

• A credible division of labor between SBC and nonprofit partner.
• Realistic commercialization milestones.
• Clear path from technical feasibility to technical validation to deployment/reimbursement context.
• Leadership and governance where team roles are not abstract titles.

Submission and compliance checklist (practical)

You cannot win by “writing quality only.” STTR submission is a compliance + quality process.

Non-negotiables

• Build and verify registrations before grant package prep.
• Confirm submission route: ASSIST, institutional S2S, or Grants.gov Workspace.
• Confirm your application tracks (new, fast-track, direct phase II) and ensure the route matches your evidence maturity.
• For any clinical-trial proposal, include RegulatoryPlan.pdf when required.
• Respect page limits and form-specific instructions in the NIH SBIR/STTR (B) guidance and NIH application guide.
• Avoid duplicate/highly overlapping submissions across identical windows.

Required documentation quality

Common application failure points:

• Missing or mismatched registrations (SAM, eRA Commons, ORCID).
• Using incorrect attachment naming or wrong attachment for trial/non-trial route.
• Choosing STTR while lacking formal nonprofit partnership logic.
• Misaligned budget asking for more than component guidance without justification.
• Weak commercialization narrative in Phase II/Fast-Track (reviewers expect market pathway evidence, not generic statements).

Strategic quality points that reviewers notice

• Explain why your STTR collaboration is essential, not optional.
• Show why your company rather than a university lab or large firm is best positioned to commercialize.
• Make partner contribution explicit: who does what, when, and at what budget share.
• Align regulatory assumptions and milestones if clinical translation is involved.

Detailed FAQ (common application questions)

Is this only for clinical products?

No. The title includes “Clinical Trial Optional,” which means a trial may be included, but non-clinical feasibility and commercialization-oriented R&D applications are also accepted.

Can foreign subsidiaries participate?

Foreign organizations are not eligible as applicants. Some unfunded collaborations can be handled in narrow contexts, but the applicant itself must be a U.S. SBC, and foreign ownership/affiliation details should be treated conservatively.

Can I submit in both PA-27-101 or PA-27-100 instead?

Not in parallel for substantially overlapping applications. The NOFO explicitly warns against duplicate or essentially identical submissions across HHS opportunities.

Do I have to share cost matching?

No cost sharing is required by the NOFO.

Can I choose direct-to-Phase II in NIH?

Yes, if conditions are met and the project has already established feasibility and merit. This still must be submitted as a “new” application and follows STTR route rules.

Is Fast-Track always better than sequential?

Only if your technical evidence and commercialization plan support both phases in one coherent package. Fast-Track can reduce funding gaps but increases proposal complexity.

How to decide whether PA-27-102 is right for your startup

Use a simple fit model before writing:

• Does the project require a nonprofit partner for R&D rigor and translation?
• Is there a realistic commercialization path beyond proof-of-concept?
• Can you commit a PI time and team structure that can pass both execution and review scrutiny?
• Are your administrative and compliance systems ready for NIH submission by your target cycle?

If you answer yes to all four, this NOFO is usually a strong option.

If partnership is weak or commercialization logic is thin, delay and build those elements first; trying to force the package late often creates low-review scores.

Review calendar and downstream implications

After submission, review follows NIH peer review pathways and advisory mechanisms. Funding decisions are based on:

• Scientific and technical merit,
• available funds,
• program alignment,
• and security/due diligence review outcomes.

Practical upshot: a brilliant idea does not always equal funding if the package cannot move from concept to scalable execution within NIH/IC policy and budget expectations.

Official links and sourcing

• Official announcement and key metadata: https://files.simpler.grants.gov/opportunities/ee37f2de-b959-4b45-86a9-43d06c944f24/attachments/f1943a30-a460-40f4-91a8-49ac401bf1f0/PA-27-102-Full-Announcement.html
• Parent opportunities index with PA-27-102 and related parent NOFOs: https://grants.nih.gov/funding/explore-nih-opportunities/parent-announcements
• Companion opportunities referenced in the NOFO: PA-27-100 (SBIR), PA-27-101, PAR-27-098.

Why this matters now

PA-27-102 is a practical route for teams that can pair science and commercialization from day one. The NOFO is broad enough for a variety of mission areas but strict enough to reject teams that skip the administrative prerequisites or submit ambiguous commercialization logic.

A strong PI package for this opportunity should look less like a grant essay and more like a project execution plan with commercial reality: who works, what they do, how much it costs, what milestones matter, what review panel will treat as persuasive, and what evidence supports market transition.

If your work fits STTR mechanics, this is one of the strongest federal options in the 2026–2027 cycle for a U.S. small business that wants to de-risk early-stage development with NIH-level credibility.